thrapy

Study Objective: To analyze and evaluate the influence of impuls7 on the condition of the patient.


Obtain surveys of stress patients:

  •   Before treatment
  •   Immediately after treatment
  •   6 weeks after treatment

Measurement of current mental state by means of
multi-dimensional Befindlichkeits questionnaire MDBF):

  •   Use of standardized and recognized medical
      psychological test procedures
  •   Administration of 24 questions, each with
      five-stage response scale (eg. 1 = “not at all    sleepy” to 5 = “very sleepy”)

 

Professional evaluation of MDBF by an independent institute (Gelszus fair market research).
The statistical analysis of MDBF questionnaires clearly documented the extremely positive effects of impuls7 on the stress levels of patients:The study participants attested to an increase in their “state of relaxation” by an average of 52.2% immediately after receiving the impuls7 treatment. Also, six weeks later, this figure remained at 50%. According to the studies, the participants felt “fresh” (by an increase of 44.3%), “relaxed” (by an increase of 34.7%) and less “restless” (down 30.5%).

The long-term benefits of impuls7 came mainly in the “relaxation” and “fresh-state” the study participants felt. Here, high levels were maintained or partially increased even further up to 6 weeks after therapy. Initial experiences also documented an even longer lasting effect.

In particular, the male subjects felt significantly relaxed after the impuls7 treatment. While before the treatments a limited number said they were relaxed (20%), this value increased immediately after treatment to 90%. Also, six weeks after the impuls7 treatment, this figure was still 50%.

Overall, participants among all investigated groups (women, men, under and over age 55) were significantly freed of restlessness. In the male control group, participants showing values of restlessness between 10% and 40% before impuls7 therapy and fell to zero after treatment.

The therapy process in the pilot study showed no side effects or treatment failures, and only a differing response to varying the intensity of impuls7 treatments could be detected.

In particular, the male subjects felt significantly relaxed after the impuls7 treatment. While before the treatments a limited number said they were relaxed (20%), this value increased immediately after treatment to 90%. Also, six weeks after the impuls7 treatment, this figure was still 50%.

Overall, participants among all investigated groups (women, men, under and over age 55) were significantly freed of restlessness. In the male control group, participants showing values of restlessness between 10% and 40% before impuls7 therapy and fell to zero after treatment.

The therapy process in the pilot study showed no side effects or treatment failures, and only a differing response to varying the intensity of impuls7 treatments could be detected.